Pre-market · Oct 6, 4:10 am ET · After hours $13.94 +0.20%
Open$13.71
Prev close$13.69
Day range$13.45 – $14.06
Volume1.12M
Market cap$1.79B
P/E (TTM)–
Dividend yield–
GENB Stock News
Headlines matching Generate Biomedicines or the GENB ticker, most recent first.
Analysts Offer Insights on NA Companies: Guidewire (GWRE) and Generate Biomedicines, Inc. (GENB)TipRanks · 9 Sep 2026
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24Market news · 7 Aug 2026
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $25Market news · 7 Aug 2026
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30Market news · 28 Aug 2026
Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)TipRanks · 17 Aug 2026
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22Market news · 17 Aug 2026
Guggenheim Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30Market news · 25 Jun 2026
Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK Hynix Inc. Sponsored GDR (OtherHXSCL)TipRanks · 25 Jun 2026
Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)TipRanks · 15 Jun 2026
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $25Market news · 8 May 2026
Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)TipRanks · 8 May 2026
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $22Market news · 14 May 2026
No comments yet — be the first to weigh in on GENB.